News / Taiwan / economic_daily
Kao Hsing Chang Realizes $61M Profit from PharmaEssentia Share Sale
Health Technology · Biotechnology · economic_daily · 2026-11-04
2008
Kao Hsing Chang has sold 353,000 shares of PharmaEssentia, generating a profit of NT$61.39 million to bolster its non-operating income.
What Happened
Investment Gain: Kao Hsing Chang announced the disposal of 353,000 shares of the biotechnology firm PharmaEssentia at an average price of NT$930.02 per share. The transaction, totaling NT$328 million, resulted in a profit of approximately NT$61.39 million, which will provide a significant boost to the company's non-operating income.
Transaction Details: The shares were sold between November 2025 and November 2026, with an original average cost basis of approximately NT$756 per share. This successful exit highlights the company's ability to capitalize on its investment portfolio and realize substantial gains.
Financial Impact: The total transaction value represents 42.36% of Kao Hsing Chang's most recent total assets and 90.37% of its equity attributable to owners of the parent. The scale of this divestiture underscores its importance to the company's overall financial position and asset management strategy.
Strategic Rationale: Management stated that the primary objective of the sale was to rebalance the company's investment portfolio. The transaction was approved by the Chairman and was conducted with an unrelated party, reflecting a standard strategic move to optimize capital allocation.